vs
亚什兰（ASH）与LifeStance Health Group, Inc.（LFST）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是LifeStance Health Group, Inc.的1.0倍（$386.0M vs $382.2M），LifeStance Health Group, Inc.净利率更高（3.1% vs -3.1%，领先6.2%），LifeStance Health Group, Inc.同比增速更快（17.4% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $46.6M），过去两年LifeStance Health Group, Inc.的营收复合增速更高（12.8% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
ASH vs LFST — 直观对比
营收规模更大
ASH
是对方的1.0倍
$382.2M
营收增速更快
LFST
高出22.1%
-4.7%
净利率更高
LFST
高出6.2%
-3.1%
自由现金流更多
ASH
多$64.4M
$46.6M
两年增速更快
LFST
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $382.2M |
| 净利润 | $-12.0M | $11.7M |
| 毛利率 | 27.2% | — |
| 营业利润率 | -1.6% | 4.7% |
| 净利率 | -3.1% | 3.1% |
| 营收同比 | -4.7% | 17.4% |
| 净利润同比 | 92.7% | 264.1% |
| 每股收益（稀释后） | $-0.26 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHLFST
| Q4 25 | $386.0M | $382.2M | ||
| Q3 25 | $477.0M | $363.8M | ||
| Q2 25 | $463.0M | $345.3M | ||
| Q1 25 | $479.0M | $333.0M | ||
| Q4 24 | $405.0M | $325.5M | ||
| Q3 24 | $521.0M | $312.7M | ||
| Q2 24 | $544.0M | $312.3M | ||
| Q1 24 | $575.0M | $300.4M |
净利润ASHLFST
| Q4 25 | $-12.0M | $11.7M | ||
| Q3 25 | $31.0M | $1.1M | ||
| Q2 25 | $-742.0M | $-3.8M | ||
| Q1 25 | $31.0M | $709.0K | ||
| Q4 24 | $-165.0M | $-7.1M | ||
| Q3 24 | $17.0M | $-6.0M | ||
| Q2 24 | $6.0M | $-23.3M | ||
| Q1 24 | $120.0M | $-21.1M |
毛利率ASHLFST
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | — | ||
| Q2 24 | 34.2% | — | ||
| Q1 24 | 28.0% | — |
营业利润率ASHLFST
| Q4 25 | -1.6% | 4.7% | ||
| Q3 25 | 12.8% | 2.0% | ||
| Q2 25 | -152.9% | -0.9% | ||
| Q1 25 | 10.6% | 0.5% | ||
| Q4 24 | -44.2% | 0.3% | ||
| Q3 24 | 6.1% | 0.0% | ||
| Q2 24 | -11.2% | -5.1% | ||
| Q1 24 | 3.7% | -5.6% |
净利率ASHLFST
| Q4 25 | -3.1% | 3.1% | ||
| Q3 25 | 6.5% | 0.3% | ||
| Q2 25 | -160.3% | -1.1% | ||
| Q1 25 | 6.5% | 0.2% | ||
| Q4 24 | -40.7% | -2.2% | ||
| Q3 24 | 3.3% | -1.9% | ||
| Q2 24 | 1.1% | -7.5% | ||
| Q1 24 | 20.9% | -7.0% |
每股收益（稀释后）ASHLFST
| Q4 25 | $-0.26 | — | ||
| Q3 25 | $0.83 | — | ||
| Q2 25 | $-16.21 | — | ||
| Q1 25 | $0.65 | — | ||
| Q4 24 | $-3.50 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.12 | — | ||
| Q1 24 | $2.39 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $248.6M |
| 总债务越低越好 | $1.4B | $282.8M |
| 股东权益账面价值 | $1.9B | $1.5B |
| 总资产 | $4.5B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.74× | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资ASHLFST
| Q4 25 | $304.0M | $248.6M | ||
| Q3 25 | $215.0M | $203.9M | ||
| Q2 25 | $207.0M | $188.9M | ||
| Q1 25 | $168.0M | $134.3M | ||
| Q4 24 | $219.0M | $154.6M | ||
| Q3 24 | $300.0M | $102.6M | ||
| Q2 24 | $399.0M | $87.0M | ||
| Q1 24 | $439.0M | $49.5M |
总债务ASHLFST
| Q4 25 | $1.4B | $282.8M | ||
| Q3 25 | $1.4B | $284.6M | ||
| Q2 25 | $1.4B | $286.4M | ||
| Q1 25 | $1.3B | $288.2M | ||
| Q4 24 | $1.3B | $290.0M | ||
| Q3 24 | $1.3B | $287.3M | ||
| Q2 24 | $1.3B | $288.0M | ||
| Q1 24 | $1.3B | $288.8M |
股东权益ASHLFST
| Q4 25 | $1.9B | $1.5B | ||
| Q3 25 | $1.9B | $1.5B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $2.6B | $1.5B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.9B | $1.4B | ||
| Q2 24 | $3.0B | $1.4B | ||
| Q1 24 | $3.1B | $1.4B |
总资产ASHLFST
| Q4 25 | $4.5B | $2.2B | ||
| Q3 25 | $4.6B | $2.1B | ||
| Q2 25 | $4.6B | $2.1B | ||
| Q1 25 | $5.2B | $2.1B | ||
| Q4 24 | $5.2B | $2.1B | ||
| Q3 24 | $5.6B | $2.1B | ||
| Q2 24 | $5.7B | $2.1B | ||
| Q1 24 | $5.9B | $2.1B |
负债/权益比ASHLFST
| Q4 25 | 0.74× | 0.19× | ||
| Q3 25 | 0.73× | 0.19× | ||
| Q2 25 | 0.73× | 0.19× | ||
| Q1 25 | 0.52× | 0.20× | ||
| Q4 24 | 0.51× | 0.20× | ||
| Q3 24 | 0.47× | 0.20× | ||
| Q2 24 | 0.45× | 0.20× | ||
| Q1 24 | 0.42× | 0.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $46.6M |
| 自由现金流率自由现金流/营收 | 28.8% | 12.2% |
| 资本支出强度资本支出/营收 | 3.6% | 2.9% |
| 现金转化率经营现金流/净利润 | — | 4.93× |
| 过去12个月自由现金流最近4个季度 | $200.0M | $110.0M |
8季度趋势，按日历期对齐
经营现金流ASHLFST
| Q4 25 | $125.0M | $57.6M | ||
| Q3 25 | $40.0M | $27.3M | ||
| Q2 25 | $115.0M | $64.4M | ||
| Q1 25 | $9.0M | $-3.1M | ||
| Q4 24 | $-30.0M | $62.3M | ||
| Q3 24 | $80.0M | $22.7M | ||
| Q2 24 | $127.0M | $44.1M | ||
| Q1 24 | $54.0M | $-21.8M |
自由现金流ASHLFST
| Q4 25 | $111.0M | $46.6M | ||
| Q3 25 | $6.0M | $17.0M | ||
| Q2 25 | $95.0M | $56.6M | ||
| Q1 25 | $-12.0M | $-10.3M | ||
| Q4 24 | $-53.0M | $56.0M | ||
| Q3 24 | $42.0M | $17.7M | ||
| Q2 24 | $98.0M | $39.0M | ||
| Q1 24 | $20.0M | $-26.9M |
自由现金流率ASHLFST
| Q4 25 | 28.8% | 12.2% | ||
| Q3 25 | 1.3% | 4.7% | ||
| Q2 25 | 20.5% | 16.4% | ||
| Q1 25 | -2.5% | -3.1% | ||
| Q4 24 | -13.1% | 17.2% | ||
| Q3 24 | 8.1% | 5.7% | ||
| Q2 24 | 18.0% | 12.5% | ||
| Q1 24 | 3.5% | -9.0% |
资本支出强度ASHLFST
| Q4 25 | 3.6% | 2.9% | ||
| Q3 25 | 7.1% | 2.8% | ||
| Q2 25 | 4.3% | 2.2% | ||
| Q1 25 | 4.4% | 2.2% | ||
| Q4 24 | 5.7% | 1.9% | ||
| Q3 24 | 7.3% | 1.6% | ||
| Q2 24 | 5.3% | 1.6% | ||
| Q1 24 | 5.9% | 1.7% |
现金转化率ASHLFST
| Q4 25 | — | 4.93× | ||
| Q3 25 | 1.29× | 25.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | -4.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
LFST
暂无分部数据
